Drugs / CardioCell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03404063 | Oct 2017 → Jul 2020 | myocardial infarction | John Paul II Hospital, Krakow | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT03423732 Comparator | Apr 2018 → May 2021 | limb ischemia | John Paul II Hospital, Krakow | Unknown | No outcome recorded |
| Phase 2/3 | NCT03418233 Comparator | Apr 2018 → Jan 2021 | heart failure | John Paul II Hospital, Krakow | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CardioCell | “compare the clinical outcomes of CardioCell administration in treatment of ischemic damages of cardiovascular system” NCT03404063 ↗ |
| Modality | Cell therapy | “Wharton's jelly mesenchymal stem cells (WJMSCs)” NCT03404063 ↗ |
| Route | Other | “The IMP administration will be performed by dedicated catheter into infarct related artery.” NCT03404063 ↗ |